# Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

> **NCT07734649** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sanofi** · enrollment: 2400 (estimated)

## Conditions studied

- Respiratory Syncytial Virus Immunization
- Human Metapneumovirus Immunization
- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** RSV+HMPV vaccine
- **BIOLOGICAL:** Control Vaccine 3
- **BIOLOGICAL:** Control Vaccine 4
- **BIOLOGICAL:** Control Vaccine 2
- **OTHER:** Placebo
- **BIOLOGICAL:** Control Vaccine 1

## Key facts

- **NCT ID:** NCT07734649
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-22
- **Primary completion:** 2028-05-03
- **Final completion:** 2028-05-03
- **Target enrollment:** 2400 (ESTIMATED)
- **Last updated:** 2026-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07734649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07734649, "Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07734649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*